Home  |  Archive  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版

Ahead of print
Authors' Accepted
Current Issue
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us

Resources & Services

Email alert

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the

AJA Club (in English)
AJA Club (in Chinese)


Societies & Institutes
Databases & Libraries
Other links


Volume 13, Issue 2 (March 2011) 13, 322–325; 10.1038/aja.2010.117

Pentoxifylline treatment and penile calcifications in men with Peyronie's disease

James F Smith1,2, Alan W Shindel1, Yun-Ching Huang1, Raul I Clavijo1, Lawrence Flechner1, Benjamin N Breyer1, Michael L Eisenberg1 and Tom F Lue1

1 Department of Urology, University of California, San Francisco, CA, USA
2 Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA 94143-0738, USA

Correspondence: Dr TF Lue, (tlue@urology.ucsf.edu)

Received 25 June 2010; Revised 6 August 2010; Accepted 26 August 2010; Published online 22 November 2010


This retrospective cohort study from a single clinical practice enrolled patients with evidence of calcified Peyronie's disease (PD) plaques detected on penile ultrasound at the time of initial presentation. The primary objective was to describe the effect of pentoxifylline (PTX) treatment on subtunical calcifications in men with PD. A PD-specific questionnaire was administered and sonographic evaluations were performed at baseline and follow-up visits. Descriptive statistics and χ2 analysis were used to characterize the effect of PTX on calcified tunical plaques. In all, 71 men (mean age: 51.9 years) with PD and sonographic evidence of calcification were identified. Of them, 62 of these men were treated with PTX for a mean duration of 1 year, and nine with vitamin E or no treatment. Improvement or stabilization in calcium burden at follow-up was noted in 57 (91.9%) of men treated with PTX versus four (44.4%) of those not treated with PTX (P<0.001). PTX users were much less likely to have a subjective worsening of their clinical condition (25.0% versus 78.3%, P=0.002). Treatment with PTX appeared to stabilize or reduce calcium content in PD plaques. A randomized controlled trial is warranted to further explore this effect.

Keywords: penile calcifications; pentoxifylline; Peyronie's disease; treatment

Keywords: penile calcifications; pentoxifylline; Peyronie’s disease; treatment

PDF | 中文摘要 |

Browse:  3091
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved